Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Holdings, Inc.ASRT · Entity 37706 | Director | May 20, 2020 | May 23, 2020 |
| Atai Beckley N.V.ATAI · Entity 72536 | Director | June 26, 2025 | June 27, 2025 |
| ROCKWELL MEDICAL, INC.RMTI · Entity 7426 | Director | May 20, 2025 | May 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Holdings, Inc.
Report date May 20, 2020 · Filed May 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,143 |
Reported balance
After 2020-05-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-20 · Grant · Acquired 49,143 · Balance 49,143 F1: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit. F3: Totals exclude shares withheld by the Issuer for applicable tax withholdings. |
| Common StockSEC Table I · non-derivative | Direct | 211,111 |
Reported balance
After 2020-05-20 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-05-20 · Grant · Acquired 211,111 · Balance 211,111 F4: One-third of these restricted stock units are scheduled to vest on each of May 20, 2021, 2022 and 2023, assuming continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time.
F2: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit.
F3: Totals exclude shares withheld by the Issuer for applicable tax withholdings.
F4: One-third of these restricted stock units are scheduled to vest on each of May 20, 2021, 2022 and 2023, assuming continued service through the applicable vesting date.
Atai Beckley N.V.
Report date June 26, 2025 · Filed June 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26 | Direct | 103,000 |
Reported balance
After 2025-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-26 · Grant · Acquired 103,000 · Balance 103,000 F1: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.
ROCKWELL MEDICAL, INC.
Report date May 20, 2025 · Filed May 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 142,062 |
Reported balance
After 2025-05-20 transaction · row 1
1 source rowRow 1 · 2025-05-20 · Grant · Acquired 50,000 · Balance 142,062 F1: Restricted stock units vest on May 20, 2026, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vest on May 20, 2026, subject to the Reporting Person's continued service to the Issuer.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AtaiBeckley Inc.
Report date September 11, 2026 · Filed September 11, 2026
Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Disposition to issuer · Disposed 4,666 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.84 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-11 · Disposition to issuer · Disposed 64,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2033-05-23 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-11 · Disposition to issuer · Disposed 64,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2035-06-26 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-11 · Disposition to issuer · Disposed 103,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2036-06-04 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-11 · Disposition to issuer · Disposed 121,968 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.
F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Zyla Life Sciences
Report date May 20, 2020 · Filed May 21, 2020
Section 16 reporting ended · disclosed 2020-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-20 transaction · row 1
1 source rowRow 1 · 2020-05-20 · Disposition to issuer · Disposed 26,953 · Balance 0 F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time.
F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 121,968 | Not disclosed Strike: $4.50 | Not disclosed |
DisclosureSEC source: 0001140361-26-036381 · form4.xml · derivative · entry 6 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,968 shares Expires 2036-06-04 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 103,000 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001140361-26-036381 · form4.xml · derivative · entry 5 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,000 shares Expires 2035-06-26 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 103,000 | Not disclosed Strike: $1.34 | Not disclosed |
DisclosureSEC source: 0001140361-26-036381 · form4.xml · derivative · entry 4 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,000 shares Expires 2034-06-13 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 64,000 | Not disclosed Strike: $1.88 | Not disclosed |
DisclosureSEC source: 0001140361-26-036381 · form4.xml · derivative · entry 3 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,000 shares Expires 2033-05-23 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 64,000 | Not disclosed Strike: $3.84 | Not disclosed |
DisclosureSEC source: 0001140361-26-036381 · form4.xml · derivative · entry 2 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,000 shares Expires 2032-05-25 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerCommon Stock | 4,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-036381 · form4.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2 · price: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 00:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | GrantStock Option · Derivative | 121,968 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001140361-26-024521 · form4.xml · derivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,968 Underlying: Common Stock · 121,968 shares Expires 2036-06-04 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date. Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 21:31 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 103,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001140361-25-024023 · form4.xml · derivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Shares · 103,000 shares Expires 2035-06-26 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026. Read SEC document |
| May 20, 2025 Filed May 21, 2025 23:03 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-051710 · tm2515860-8_4seq1.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,062 F1 · kind: Restricted stock units vest on May 20, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 21:00 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 103,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001140361-24-030206 · form4.xml · derivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Shares · 103,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 13, 2025. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:05 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 36,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-064811 · tm2415466-2_4seq1.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,062 F1 · kind: Restricted stock units vest on May 21, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Effective on May 13, 2022, the Issuer effected a 1-for-11 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:23 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 24,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064642 · tm2316982-5_4seq1.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,316 F1 · kind: Restricted stock units vest on May 23, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:17 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 64,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000950170-23-024246 · ownership.xml · derivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Shares · 64,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or May 16, 2024. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:32 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-069684 · tm2218111-2_4seq1.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,601 F1 · kind: Restricted stock units vest on June 7, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 25, 2022 Filed May 27, 2022 21:55 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 64,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0000899243-22-019978 · doc4.xml · derivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Shares · 64,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The stock option shall vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or May 25, 2023. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:30 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 128,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0000899243-21-035675 · doc4.xml · derivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Shares · 128,000 shares Expires 2031-09-10 F1 · derivative.exercise_date: The stock option shall vest with respect to a third of the underlying common shares on June 17, 2022 and in 24 substantially equal monthly installments thereafter until June 17, 2024. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:16 UTC | Atai Beckley N.V. ATAI · Entity 72536 | PurchaseCommon Shares | 4,666 | $15.00 | $69,990.00 |
DisclosureSEC source: 0000899243-21-025739 · doc4.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:26 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 72,857 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001628280-21-012671 · wf-form4_162439714172479.xml · derivative · entry 2 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,857 Underlying: Common Stock · 72,857 shares Expires 2031-06-17 F3 · derivative.exercise_date: Stock options shall vest in accordance with the following vesting schedule: (1) one-half (fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2023; and (2) the final one-half (remaining fifty percent) of the shares of Common Stock subject to this Option shall vest on June 17, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 21:26 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012671 · wf-form4_162439714172479.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,601 F1 · kind: Restricted stock units vest on June 17, 2022, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 18,601 shares of common stock underlying unvested restricted stock units that vest on December 11, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:30 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCall Option (right to buy) · Derivative | 26,042 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001628280-20-017530 · wf-form4_160806782689725.xml · derivative · entry 2 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,042 Underlying: Call Option (right to buy) · Not disclosed shares Expires 2030-12-11 F2 · derivative.exercise_date: Stock options vest on December 11, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:30 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 18,601 | $1.12 | $20,833.12 |
DisclosureSEC source: 0001628280-20-017530 · wf-form4_160806782689725.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,601 F1 · kind: Restricted stock units vest on December 11, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 20, 2020 Filed May 21, 2020 16:32 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Disposition to issuerCommon Stock | 26,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-064794 · a4.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · kind: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. F1 · price: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · price: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:55 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 211,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-065544 · a4.xml · nonDerivative · entry 2 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,111 F4 · shares: One-third of these restricted stock units are scheduled to vest on each of May 20, 2021, 2022 and 2023, assuming continued service through the applicable vesting date. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:55 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 49,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-065544 · a4.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,143 F1 · kind: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · kind: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit. F3 · shares: Totals exclude shares withheld by the Issuer for applicable tax withholdings. F1 · price: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · price: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit. F3 · balance_after: Totals exclude shares withheld by the Issuer for applicable tax withholdings. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 18:13 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005106 · edgar.xml · derivative · entry 3 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into Common Stock on a one-for-one basis. F3 · derivative.exercise_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. F3 · derivative.expiration_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 18:13 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Tax withholdingCommon Stock | 952 | $1.75 | $1,666.00 |
DisclosureSEC source: 0001179110-20-005106 · edgar.xml · nonDerivative · entry 2 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,715 F1 · shares: Represents shares withheld to pay taxes applicable to vesting of restricted stock units. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 18:13 UTC | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionCommon Stock | 6,667 | $1.75 | $11,667.25 |
DisclosureSEC source: 0001179110-20-005106 · edgar.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document |
| April 23, 2020 Filed Apr 28, 2020 19:40 UTC Amendment | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005216 · edgar.xml · derivative · entry 3 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into Common Stock on a one-for-one basis. F3 · derivative.exercise_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. F3 · derivative.expiration_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document |
| April 23, 2020 Filed Apr 28, 2020 19:40 UTC Amendment | Zyla Life Sciences ZCOR · Entity 148990 | Tax withholdingCommon Stock | 1,805 | $1.75 | $3,158.75 |
DisclosureSEC source: 0001179110-20-005216 · edgar.xml · nonDerivative · entry 2 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,862 F1 · shares: Represents shares withheld to pay taxes applicable to vesting of restricted stock units. Read SEC document |
| April 23, 2020 Filed Apr 28, 2020 19:40 UTC Amendment | Zyla Life Sciences ZCOR · Entity 148990 | Exercise / conversionCommon Stock | 6,667 | $1.75 | $11,667.25 |
DisclosureSEC source: 0001179110-20-005216 · edgar.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 20:43 UTC | Zyla Life Sciences ZCOR · Entity 148990 | GrantCommon Stock | 13,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-003203 · edgar.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,620 F1 · shares: Represents restricted stock units, which vest the day prior to the Company's annual meeting of stockholders to be held in 2021. Read SEC document |
| April 23, 2019 Filed Apr 24, 2019 20:52 UTC | Zyla Life Sciences ZCOR · Entity 148990 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005159 · edgar.xml · nonDerivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 20:09 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 51,817 | Not disclosed Strike: $3.67 | Not disclosed |
DisclosureSEC source: 0001179110-19-001264 · edgar.xml · derivative · entry 2 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,817 shares Expires 2027-05-01 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 20:09 UTC | Zyla Life Sciences EGLT · Entity 148990 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $0.60 | Not disclosed |
DisclosureSEC source: 0001179110-19-001264 · edgar.xml · derivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2028-05-14 F1 · price: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. F1 · derivative.exercise_date: Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the "Plan"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan. Read SEC document |
| May 14, 2018 Filed May 15, 2018 16:19 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-006810 · edgar.xml · derivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: These options to purchase shares of common stock vest 100% on the day prior to the date of the Corporation's annual meeting of stockholders to be held in 2019 subject to the director's continued service through the vesting date. Read SEC document |
| May 01, 2017 Filed May 2, 2017 16:40 UTC | Zyla Life Sciences EGLT · Entity 148990 | GrantStock Option (Right to Buy) · Derivative | 51,817 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001179110-17-006391 · edgar.xml · derivative · entry 1 Smiley Andrea Heslin · CIK 0001703767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,817 Underlying: Common Stock · 51,817 shares Expires 2027-05-01 F1 · derivative.exercise_date: The option vests with respect to one-fourth of the underlying shares on each of the first four anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.